Clinical Trial Update: Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TAC chemotherapy with or without zoledronic acid in HER2-negative breast cancer; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TAC
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Borstkanker Onderzoek Groep | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED